Brand's Off-Label Promotion: Valuable Tool For Generics
On Nov. 3, GlaxoSmithKline PLC announced that it will pay $3 billion to settle civil and criminal allegations that it promoted the drug Avandia for off-label uses.[1] This is only the...To view the full article, register now.
Already a subscriber? Click here to view full article